PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new…
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from…
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex…
First patient recruited at leading Israeli site accelerating enrollment momentum across global study of CMND-100 Vancouver, Canada, Nov. 25, 2025…
ANN ARBOR, Mich., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a…
NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in…
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b…
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to…
Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year…
WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics…